EV/Sales Ratio: 2.63x
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 2.63x is 18% above its 5-year average of 2.22x, near the high end of its 5-year range (1.73x–2.74x).
As of Friday, June 26, 2026. 4.36% above its 12-month average of 2.52x.
DGX EV/Sales Ratio Chart
DGX Average EV/Sales Ratio Chart
DGX Current vs Average EV/Sales Ratio Chart
DGX EV/Sales Ratio Metrics
EV/SALES RATIO
2.63x
EV/SALES RATIO AVG TTM
2.52x
EV/SALES RATIO AVG 3Y
2.37x
EV/SALES RATIO AVG 5Y
2.22x
EV/SALES RATIO AVG 10Y
2.27x
EV/SALES RATIO AVG 15Y
2.10x
EV/SALES RATIO AVG 20Y
2.03x
CURRENT VS TTM AVG
+4.36%
CURRENT VS 3Y AVG
+10.98%
CURRENT VS 5Y AVG
+18.37%
CURRENT VS 10Y AVG
+15.92%
CURRENT VS 15Y AVG
+25.40%
CURRENT VS 20Y AVG
+29.37%
DGX Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated (DGX) | $22.83B | 2.63x | 2.52x | 2.37x | 2.22x |
| BioNTech SE (BNTX)vs › | $22.76B | 3.54x | 4.14x | 3.74x | 3.35x |
| United Therapeutics Corporation (UTHR)vs › | $23.07B | 7.75x | 6.59x | 5.75x | 5.79x |
| Moderna, Inc. (MRNA)vs › | $23.71B | 10.33x | 6.22x | 5.10x | 6.63x |
| Labcorp Holdings Inc. (LH)vs › | $21.83B | 2.00x | 2.09x | 2.00x | 1.88x |
| Incyte Corporation (INCY)vs › | $21.48B | 3.51x | 3.33x | 3.05x | 3.67x |
| Waters Corporation (WAT)vs › | $24.57B | 9.56x | 7.11x | 7.17x | 7.32x |
| Mettler-Toledo International Inc. (MTD)vs › | $25.13B | 6.70x | 7.33x | 7.49x | 8.15x |
| STERIS plc (STE)vs › | $20.52B | 3.77x | 4.44x | 4.78x | 5.11x |
| Veeva Systems Inc. (VEEV)vs › | $25.68B | 7.37x | 12.17x | 13.24x | 15.50x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Quest Diagnostics Incorporated (DGX)?
- The EV/Sales ratio for DGX stock is 2.63x.
- Is Quest Diagnostics Incorporated's EV/Sales ratio high or low?
- The EV/Sales ratio of 2.63x is 18% above its 5-year average of 2.22x, near the high end of its 5-year range (1.73x–2.74x).
- What is the TTM average EV/Sales ratio for Quest Diagnostics Incorporated (DGX)?
- The TTM average EV/Sales ratio for DGX stock is 2.52x.
- What is the 3Y average EV/Sales ratio for Quest Diagnostics Incorporated (DGX)?
- The 3Y average EV/Sales ratio for DGX stock is 2.37x.
- What is the 5Y average EV/Sales ratio for Quest Diagnostics Incorporated (DGX)?
- The 5Y average EV/Sales ratio for DGX stock is 2.22x.
- What is the 10Y average EV/Sales ratio for Quest Diagnostics Incorporated (DGX)?
- The 10Y average EV/Sales ratio for DGX stock is 2.27x.
- What is the 15Y average EV/Sales ratio for Quest Diagnostics Incorporated (DGX)?
- The 15Y average EV/Sales ratio for DGX stock is 2.10x.
- What is the 20Y average EV/Sales ratio for Quest Diagnostics Incorporated (DGX)?
- The 20Y average EV/Sales ratio for DGX stock is 2.03x.
DGX EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-25 | 2.63x |
| 2026-06-24 | 2.60x |
| 2026-06-23 | 2.54x |
| 2026-06-22 | 2.51x |
| 2026-06-18 | 2.52x |
| 2026-06-17 | 2.55x |
| 2026-06-16 | 2.58x |
| 2026-06-15 | 2.59x |
| 2026-06-12 | 2.60x |
| 2026-06-11 | 2.61x |
| 2026-06-10 | 2.61x |
| 2026-06-09 | 2.62x |
| 2026-06-08 | 2.54x |
| 2026-06-05 | 2.57x |
| 2026-06-04 | 2.53x |
| 2026-06-03 | 2.51x |
| 2026-06-02 | 2.50x |
| 2026-06-01 | 2.49x |
| 2026-05-29 | 2.52x |
| 2026-05-28 | 2.53x |
| 2026-05-27 | 2.51x |
| 2026-05-26 | 2.50x |
| 2026-05-22 | 2.52x |
| 2026-05-21 | 2.51x |
| 2026-05-20 | 2.51x |
| 2026-05-19 | 2.47x |
| 2026-05-18 | 2.47x |
| 2026-05-15 | 2.44x |
| 2026-05-14 | 2.45x |
| 2026-05-13 | 2.48x |
| 2026-05-12 | 2.47x |
| 2026-05-11 | 2.47x |
| 2026-05-08 | 2.44x |
| 2026-05-07 | 2.48x |
| 2026-05-06 | 2.46x |
| 2026-05-05 | 2.48x |
| 2026-05-04 | 2.49x |
| 2026-05-01 | 2.50x |
| 2026-04-30 | 2.51x |
| 2026-04-29 | 2.46x |
| 2026-04-28 | 2.52x |
| 2026-04-27 | 2.54x |
| 2026-04-24 | 2.53x |
| 2026-04-23 | 2.57x |
| 2026-04-22 | 2.61x |
| 2026-04-21 | 2.67x |
| 2026-04-20 | 2.58x |
| 2026-04-17 | 2.57x |
| 2026-04-16 | 2.53x |
| 2026-04-15 | 2.53x |
| 2026-04-14 | 2.56x |
| 2026-04-13 | 2.55x |
| 2026-04-10 | 2.53x |
| 2026-04-09 | 2.60x |
| 2026-04-08 | 2.61x |
| 2026-04-07 | 2.59x |
| 2026-04-06 | 2.61x |
| 2026-04-02 | 2.60x |
| 2026-04-01 | 2.60x |
| 2026-03-31 | 2.58x |
| 2026-03-30 | 2.59x |
| 2026-03-27 | 2.57x |
| 2026-03-26 | 2.60x |
| 2026-03-25 | 2.58x |
| 2026-03-24 | 2.58x |
| 2026-03-23 | 2.57x |
| 2026-03-20 | 2.57x |
| 2026-03-19 | 2.56x |
| 2026-03-18 | 2.57x |
| 2026-03-17 | 2.60x |
| 2026-03-16 | 2.61x |
| 2026-03-13 | 2.62x |
| 2026-03-12 | 2.63x |
| 2026-03-11 | 2.62x |
| 2026-03-10 | 2.63x |
| 2026-03-09 | 2.63x |
| 2026-03-06 | 2.61x |
| 2026-03-05 | 2.66x |
| 2026-03-04 | 2.70x |
| 2026-03-03 | 2.70x |
| 2026-03-02 | 2.72x |
| 2026-02-27 | 2.74x |
| 2026-02-26 | 2.73x |
| 2026-02-25 | 2.71x |
| 2026-02-24 | 2.73x |
| 2026-02-23 | 2.71x |
| 2026-02-20 | 2.66x |
| 2026-02-19 | 2.66x |
| 2026-02-18 | 2.68x |
| 2026-02-17 | 2.69x |
| 2026-02-13 | 2.70x |
| 2026-02-12 | 2.70x |
| 2026-02-11 | 2.73x |
| 2026-02-10 | 2.69x |
| 2026-02-09 | 2.54x |
| 2026-02-06 | 2.53x |
| 2026-02-05 | 2.55x |
| 2026-02-04 | 2.52x |
| 2026-02-03 | 2.48x |
| 2026-02-02 | 2.48x |
| 2026-01-30 | 2.50x |
| 2026-01-29 | 2.45x |
| 2026-01-28 | 2.45x |
| 2026-01-27 | 2.47x |
| 2026-01-26 | 2.45x |
| 2026-01-23 | 2.43x |
| 2026-01-22 | 2.45x |
| 2026-01-21 | 2.47x |
| 2026-01-20 | 2.52x |
| 2026-01-16 | 2.52x |
| 2026-01-15 | 2.53x |
| 2026-01-14 | 2.49x |
| 2026-01-13 | 2.42x |
| 2026-01-12 | 2.38x |
| 2026-01-09 | 2.37x |
| 2026-01-08 | 2.40x |
| 2026-01-07 | 2.40x |
| 2026-01-06 | 2.43x |
| 2026-01-05 | 2.36x |
| 2026-01-02 | 2.36x |
| 2025-12-31 | 2.36x |
| 2025-12-30 | 2.38x |
| 2025-12-29 | 2.38x |
| 2025-12-26 | 2.38x |
| 2025-12-24 | 2.38x |
| 2025-12-23 | 2.37x |
| 2025-12-22 | 2.38x |
| 2025-12-19 | 2.38x |
| 2025-12-18 | 2.38x |
| 2025-12-17 | 2.41x |
| 2025-12-16 | 2.41x |
| 2025-12-15 | 2.47x |
| 2025-12-12 | 2.45x |
| 2025-12-11 | 2.44x |
| 2025-12-10 | 2.42x |
| 2025-12-09 | 2.42x |
| 2025-12-08 | 2.44x |
| 2025-12-05 | 2.45x |
| 2025-12-04 | 2.47x |
| 2025-12-03 | 2.45x |
| 2025-12-02 | 2.45x |
| 2025-12-01 | 2.46x |
| 2025-11-28 | 2.52x |
| 2025-11-26 | 2.52x |
| 2025-11-25 | 2.55x |
| 2025-11-24 | 2.53x |
| 2025-11-21 | 2.54x |
| 2025-11-20 | 2.50x |
| 2025-11-19 | 2.49x |
| 2025-11-18 | 2.48x |
| 2025-11-17 | 2.49x |
| 2025-11-14 | 2.50x |
| 2025-11-13 | 2.50x |
| 2025-11-12 | 2.49x |
| 2025-11-11 | 2.52x |
| 2025-11-10 | 2.47x |
| 2025-11-07 | 2.42x |
| 2025-11-06 | 2.39x |
| 2025-11-05 | 2.40x |
| 2025-11-04 | 2.40x |
| 2025-11-03 | 2.41x |
| 2025-10-31 | 2.38x |
| 2025-10-30 | 2.38x |
| 2025-10-29 | 2.37x |
| 2025-10-28 | 2.41x |
| 2025-10-27 | 2.43x |
| 2025-10-24 | 2.45x |
| 2025-10-23 | 2.46x |
| 2025-10-22 | 2.44x |
| 2025-10-21 | 2.47x |
| 2025-10-20 | 2.62x |
| 2025-10-17 | 2.61x |
| 2025-10-16 | 2.58x |
| 2025-10-15 | 2.59x |
| 2025-10-14 | 2.57x |
| 2025-10-13 | 2.54x |
| 2025-10-10 | 2.55x |
| 2025-10-09 | 2.52x |
| 2025-10-08 | 2.52x |
| 2025-10-07 | 2.53x |
| 2025-10-06 | 2.49x |
| 2025-10-03 | 2.50x |
| 2025-10-02 | 2.52x |
| 2025-10-01 | 2.53x |
| 2025-09-30 | 2.62x |
| 2025-09-29 | 2.60x |
| 2025-09-26 | 2.61x |
| 2025-09-25 | 2.57x |
| 2025-09-24 | 2.58x |
| 2025-09-23 | 2.58x |
| 2025-09-22 | 2.56x |
| 2025-09-19 | 2.55x |
| 2025-09-18 | 2.55x |
| 2025-09-17 | 2.53x |
| 2025-09-16 | 2.51x |
| 2025-09-15 | 2.52x |
| 2025-09-12 | 2.54x |
| 2025-09-11 | 2.55x |
| 2025-09-10 | 2.51x |
| 2025-09-09 | 2.54x |
| 2025-09-08 | 2.54x |
| 2025-09-05 | 2.55x |
| 2025-09-04 | 2.51x |
| 2025-09-03 | 2.50x |
| 2025-09-02 | 2.50x |
| 2025-08-29 | 2.53x |
| 2025-08-28 | 2.50x |
| 2025-08-27 | 2.51x |
| 2025-08-26 | 2.51x |
| 2025-08-25 | 2.50x |
| 2025-08-22 | 2.51x |
| 2025-08-21 | 2.55x |
| 2025-08-20 | 2.56x |
| 2025-08-19 | 2.54x |
| 2025-08-18 | 2.50x |
| 2025-08-15 | 2.51x |
| 2025-08-14 | 2.49x |
| 2025-08-13 | 2.50x |
| 2025-08-12 | 2.50x |
| 2025-08-11 | 2.49x |
| 2025-08-08 | 2.48x |
| 2025-08-07 | 2.45x |
| 2025-08-06 | 2.43x |
| 2025-08-05 | 2.44x |
| 2025-08-04 | 2.43x |
| 2025-08-01 | 2.41x |
| 2025-07-31 | 2.37x |
| 2025-07-30 | 2.39x |
| 2025-07-29 | 2.38x |
| 2025-07-28 | 2.38x |
| 2025-07-25 | 2.39x |
| 2025-07-24 | 2.42x |
| 2025-07-23 | 2.41x |
| 2025-07-22 | 2.61x |
| 2025-07-21 | 2.48x |
| 2025-07-18 | 2.49x |
| 2025-07-17 | 2.50x |
| 2025-07-16 | 2.49x |
| 2025-07-15 | 2.48x |
| 2025-07-14 | 2.50x |
| 2025-07-11 | 2.50x |
| 2025-07-10 | 2.54x |
| 2025-07-09 | 2.56x |
| 2025-07-08 | 2.55x |
| 2025-07-07 | 2.56x |
| 2025-07-03 | 2.60x |
| 2025-07-02 | 2.59x |
| 2025-07-01 | 2.62x |
| 2025-06-30 | 2.63x |
| 2025-06-27 | 2.61x |
| 2025-06-26 | 2.60x |
| 2025-06-25 | 2.62x |
| 2025-06-24 | 2.63x |
| 2025-06-23 | 2.63x |
| 2025-06-20 | 2.62x |
| 2025-06-18 | 2.63x |
| 2025-06-17 | 2.62x |
| 2025-06-16 | 2.65x |
| 2025-06-13 | 2.63x |
| 2025-06-12 | 2.62x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis